Allergan

Latest stories

18h
FOX Business
These 3 Stocks Tripled In 12 MonthsAfter suffering through a long period in which its stock price got cut in half,
These 3 Stocks Tripled In 12 Months
FOX Business / Posted 18 hours ago
After suffering through a long period in which its stock price got cut in half, Tobira received a buyout offer from Allergan (NYSE: AGN) that sent the biotech up by more than 700% in a single day. That brought its overall 12-month return to... Read more
18h
FOX Business
These 3 Stocks Tripled In 12 MonthsAfter suffering through a long period in which its stock price got cut in half,
These 3 Stocks Tripled In 12 Months
FOX Business / Posted 18 hours ago
After suffering through a long period in which its stock price got cut in half, Tobira received a buyout offer from Allergan (NYSE: AGN) that sent the biotech up by more than 700% in a single day. That brought its overall 12-month return to... Read more
1d
Detroit Free Press
WSU research leads to algae treatment for blindnessRetroSense Therapeutics, which is now based at the Ann Arbor SPARK business acc
WSU research leads to algae treatment for blindness
Detroit Free Press / Posted yesterday
RetroSense Therapeutics, which is now based at the Ann Arbor SPARK business accelerator, was acquired this month by Allergan, a $4 billion-a-year maker of skin and eye care products. The company's treatment uses a virus to deliver a... Read more
1d
Orange County Business Journal
Allergan OC: 1,563 Jobs, $307M PayrollAllergan Plc’s local operations provide 1,563 jobs here with a combined payroll
Allergan OC: 1,563 Jobs, $307M Payroll
Orange County Business Journal / Posted yesterday
Allergan Plc’s local operations provide 1,563 jobs here with a combined payroll of about $307 million, based on the company’s average salary statewide, an economic impact study said. The drugmaker has 2,233 full-time equivalent employees statewide,... Read more
1d
The New Zealand Herald
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca
Drugmaker Pfizer decides not to break up business
The New Zealand Herald / Posted yesterday
It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
20 related stories
1d
Arkansas Democrat-Gazette
Seeing little to gain, Pfizer opts against splitting firm in twoIt also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca
Seeing little to gain, Pfizer opts against splitting firm in two
Arkansas Democrat-Gazette / Posted yesterday
It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
20 related stories
2d
asianage
Pfizer decides against split-up; more deals seen likelyIt bought Medivation for its blockbuster prostate cancer drug Xtandi. Pfizer's
Pfizer decides against split-up; more deals seen likely
asianage / Posted 2 days ago
It bought Medivation for its blockbuster prostate cancer drug Xtandi. Pfizer's $160 billion deal to buy Irish drugmaker Allergan Inc collapsed in April after a change in US law had negated the tax benefits for companies moving corporate... Read more
15 related stories
2d
Boston Globe
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, of Britain’s AstraZeneca
Drugmaker Pfizer decides not to break up business
Boston Globe / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, of Britain’s AstraZeneca PLC in 2014 and this year of Ireland’s Allergan PLC. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
20 related stories
2d
The Columbian
Pfizer decides not to split business in twoIt also attempted and failed at two mega-acquisitions, of Britain’s AstraZeneca
Pfizer decides not to split business in two
The Columbian / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, of Britain’s AstraZeneca Plc in 2014 and this year of Ireland’s Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
15 related stories
2d
The Register NorthJersey.com
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca
Drugmaker Pfizer decides not to break up business
The Register NorthJersey.com / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
20 related stories
2d
The Signal
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca
Drugmaker Pfizer decides not to break up business
The Signal / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
20 related stories
2d
NBC Philadelphia
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC Philadelphia / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
Brandon Sun
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca
Drugmaker Pfizer decides not to break up business
Brandon Sun / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, of Britain's AstraZeneca Plc in 2014 and this year of Ireland's Allergan Plc. Both those deals had been structured as tax inversions, meant to allow Pfizer to move its headquarters from... Read more
15 related stories
2d
NBC New York
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC New York / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
NBC Los Angeles
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC Los Angeles / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
NBC Washington
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC Washington / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
NBC Dallas Fort Worth
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC Dallas Fort Worth / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
NBC Bay Area
Pfizer Decides Not to Break Up BusinessIt also attempted and failed at two mega-acquisitions, first of Britain's Astra
Pfizer Decides Not to Break Up Business
NBC Bay Area / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain's AstraZeneca Plc and this year of Ireland's Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
20 related stories
2d
Providence Business News
Pfizer decides not to split, ending years of speculationof it called an “extensive evaluation.” The decision follows the collapse of P
Pfizer decides not to split, ending years of speculation
Providence Business News / Posted 2 days ago
of it called an “extensive evaluation.” The decision follows the collapse of Pfizer’s attempted $160 billion merger with Allergan PLC in April, a deal that would have shifted the company’s tax address overseas and bulked up one of the units... Read more
15 related stories
2d
RTE News
Pfizer abandons plan to split into two companiesdecision not to create two publicly traded companies follows the collapse of it
Pfizer abandons plan to split into two companies
RTE News / Posted 2 days ago
decision not to create two publicly traded companies follows the collapse of its planned $160 billion acquisition of Allergan after a change in tax law took away the tax benefits of the deal. Investors were expecting the company to step back... Read more
15 related stories
2d
The Washington Times
Drugmaker Pfizer decides not to break up businessIt also attempted and failed at two mega-acquisitions, first of Britain’s Astra
Drugmaker Pfizer decides not to break up business
The Washington Times / Posted 2 days ago
It also attempted and failed at two mega-acquisitions, first of Britain’s AstraZeneca Plc and this year of Ireland’s Allergan Plc. Last month, it said it would spend about $14 billion to buy cancer drug developer Medivation, and it was... Read more
15 related stories
2d
Channel NewsAsia
Pfizer abandons plan to split into two companiesdecision not to create two publicly traded companies follows the collapse of it
Pfizer abandons plan to split into two companies
Channel NewsAsia / Posted 2 days ago
decision not to create two publicly traded companies follows the collapse of its planned US$160 billion acquisition of Allergan Inc after a change in tax law took away the tax benefits of the deal. Investors were expecting the company to step... Read more
15 related stories
2d
USA Today
Pfizer eschews proposal to split into twonew rules on corporate tax inversions that effectively scuttled Pfizer's $160 b
Pfizer eschews proposal to split into two
USA Today / Posted 2 days ago
new rules on corporate tax inversions that effectively scuttled Pfizer's $160 billion combination with Ireland-based Allergan. Pfizer shares (PFE) fell 1.1% in pre-market trading to $33.87. Follow USA TODAY reporter Nathan Bomey on Twitter... Read more
2d
Fortune
Pfizer Has Abandoned Its Plan to Split Into Two Companiestheir focus to whether Pfizer would split after the company terminated a $160 b
Pfizer Has Abandoned Its Plan to Split Into Two Companies
Fortune / Posted 2 days ago
their focus to whether Pfizer would split after the company terminated a $160 billion deal to acquire Irish drugmaker Allergan agn in April due to new U.S. tax inversion rules. Pfizer said on Monday the decision to not split itself would not... Read more
15 related stories
2d
Market Watch
Pfizer says it won’t split into two separate companiescompanies. In April Pfizer said it would make a decision on a potential split
Pfizer says it won’t split into two separate companies
Market Watch / Posted 2 days ago
companies. In April Pfizer said it would make a decision on a potential split by the end of the year, after it and Allergan PLC AGN, +0.21% ended their planned $150 billion merger as the Obama administration took aim at the deal that would... Read more
15 related stories
2d
The Irish Times
Drugmaker Pfizer abandons plan to split into twotheir focus to whether Pfizer would split after the company terminated a $160 b
Drugmaker Pfizer abandons plan to split into two
The Irish Times / Posted 2 days ago
their focus to whether Pfizer would split after the company terminated a $160 billion deal to acquire Irish drugmaker Allergan in April due to new tax inversion rules. Pfizer said on Monday the decision to not split itself would not impact... Read more
15 related stories
2d
FOX Business
Pfizer Won't Pursue A Splitolder products. In April Pfizer said it would make a decision on a potential s
Pfizer Won't Pursue A Split
FOX Business / Posted 2 days ago
older products. In April Pfizer said it would make a decision on a potential split by the end of the year, after it and Allergan ended their planned $150 billion merger as the Obama administration took aim at the deal that would have moved the... Read more
15 related stories
2d
FOX Business
Pfizer Won't Pursue A Splitolder products. In April Pfizer said it would make a decision on a potential s
Pfizer Won't Pursue A Split
FOX Business / Posted 2 days ago
older products. In April Pfizer said it would make a decision on a potential split by the end of the year, after it and Allergan ended their planned $150 billion merger as the Obama administration took aim at the deal that would have moved the... Read more
15 related stories
2d
Channel NewsAsia
Pfizer abandons plan to split into twotheir focus to whether Pfizer would split after the company terminated a US$160
Pfizer abandons plan to split into two
Channel NewsAsia / Posted 2 days ago
their focus to whether Pfizer would split after the company terminated a US$160 billion deal to acquire Irish drugmaker Allergan Plc in April due to new U.S. tax inversion rules. Pfizer said on Monday the decision to not split itself would not... Read more
15 related stories
2d
MedCity News
One upside to the drug price pressure debate: more biopharma dealsseveral high profile CEOs here). In an impressive sign of industry leadership a
One upside to the drug price pressure debate: more biopharma deals
MedCity News / Posted 2 days ago
several high profile CEOs here). In an impressive sign of industry leadership and self-regulation, Brent Saunders, CEO of Allergan, has announced a pricing pledge to limit increases to “no more than once per year and, when we do, they will be... Read more
2d
FOX Business
Pfizer Decides Against Splitting Into Two Companiescompanies, something the drug giant had been mulling over for years, but reigni
Pfizer Decides Against Splitting Into Two Companies
FOX Business / Posted 2 days ago
companies, something the drug giant had been mulling over for years, but reignited after its proposed merger with Allergan PLC fell through. The company said it determined that the best course to maximize shareholder value was to manage... Read more
2d
FOX Business
Pfizer Decides Against Splitting Into Two Companiescompanies, something the drug giant had been mulling over for years, but reigni
Pfizer Decides Against Splitting Into Two Companies
FOX Business / Posted 2 days ago
companies, something the drug giant had been mulling over for years, but reignited after its proposed merger with Allergan PLC fell through. The company said it determined that the best course to maximize shareholder value was to manage... Read more
3d
Orange County Register
Biz briefly: Microsemi chairman elected to Chapman trustees; Kia employees grant $50K; business seminars for OctoberGenetics in Aliso Viejo; Mitchell Brin, senior vice president for Global Drug D
Biz briefly: Microsemi chairman elected to Chapman trustees; Kia employees grant $50K; business seminars for October
Orange County Register / Posted 3 days ago
Genetics in Aliso Viejo; Mitchell Brin, senior vice president for Global Drug Development and chief scientific officer for Allergan PLC's Botox unit in Irvine; Stuart McClure, founder/chief executive of Cylance Inc. in Irvine; Dr. Benjamin Park,... Read more
4d
News-Medical-Net
Allergan wins FDA approval to market new NATRELLE INSPIRA Cohesive breast implantsAllergan plc (NYSE: AGN) today announced the company has received approval from
Allergan wins FDA approval to market new NATRELLE INSPIRA Cohesive breast implants
News-Medical-Net / Posted 4 days ago
Allergan plc (NYSE: AGN) today announced the company has received approval from the U.S. Food and Drug Administration (FDA) to market NATRELLE INSPIRA®Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision... Read more
4d
FOX Business
3 Dirt-Cheap Dividend Stocks You Can Buy Right Nowfor income-seeking investors: Image source: Teva. Second, Teva has greatly di
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
FOX Business / Posted 4 days ago
for income-seeking investors: Image source: Teva. Second, Teva has greatly diversified its revenue base by acquiring Allergan's (NYSE: AGN) generic-drug unit this year, further reducing the risk of falling Copaxone sales. This deal is also... Read more
4d
FOX Business
3 Dirt-Cheap Dividend Stocks You Can Buy Right Nowfor income-seeking investors: Image source: Teva. Second, Teva has greatly di
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
FOX Business / Posted 4 days ago
for income-seeking investors: Image source: Teva. Second, Teva has greatly diversified its revenue base by acquiring Allergan's (NYSE: AGN) generic-drug unit this year, further reducing the risk of falling Copaxone sales. This deal is also... Read more
5d
Business Wire
Pharmaceuticals Manufacturers ( - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Incmarket and delivers a comprehensive individual analysis on the top 90 companies
Pharmaceuticals Manufacturers ( - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc
Business Wire / Posted 5 days ago
market and delivers a comprehensive individual analysis on the top 90 companies, including Pfizer Inc, Novo Nordisk A/S And Allergan Inc. This report includes a wealth of information on the financial trends over the past four years. The latest... Read more
5 related stories
5d
FOX Business
Biotech Etf Rally Gains Momentum After Political Slowdownrisks in an election season. Trending on ETF Trends IBB’s surge “comes on the
Biotech Etf Rally Gains Momentum After Political Slowdown
FOX Business / Posted 5 days ago
risks in an election season. Trending on ETF Trends IBB’s surge “comes on the heels of two major recent acquisitions by Allergan in the biotech field. The Ireland-based company announced its $1.7 billion deal with Tobira Therapeutics on Tuesday,... Read more
5d
FOX Business
Biotech Etf Rally Gains Momentum After Political Slowdownon ETF Trends Continue Reading Below IBB’s surge “comes on the heels of two m
Biotech Etf Rally Gains Momentum After Political Slowdown
FOX Business / Posted 5 days ago
on ETF Trends Continue Reading Below IBB’s surge “comes on the heels of two major recent acquisitions by Allergan in the biotech field. The Ireland-based company announced its $1.7 billion deal with Tobira Therapeutics on Tuesday,... Read more
5d
Chicago Tribune
Allergan CEO is shocked (shocked!) by insane drug pricesThe chief executive of a major drug company is a hero because he won’t rip off
Allergan CEO is shocked (shocked!) by insane drug prices
Chicago Tribune / Posted 5 days ago
The chief executive of a major drug company is a hero because he won’t rip off customers any more. Brent Saunders, CEO of Allergan, the company best known for making Botox, made headlines this week after posting an announcement on his company’s... Read more
6d
The Economic Times
Sun Pharmaceuticals among bidders for Bayer’s dermatology brandssaid. Sun Pharma declined to comment on the development. Apart from Sun, numbe
Sun Pharmaceuticals among bidders for Bayer’s dermatology brands
The Economic Times / Posted 6 days ago
said. Sun Pharma declined to comment on the development. Apart from Sun, number one ranked generics giant Teva, Perrigo, Allergan and Spanish pharmaceutical company Almirall in combination with Galderma are also said to be considering a bid for... Read more
6d
Reuters
Vanda Pharmaceuticals prepares to explore a salewhose drug Nucynta treats pain, is also preparing to explore a sale, Reuters re
Vanda Pharmaceuticals prepares to explore a sale
Reuters / Posted 6 days ago
whose drug Nucynta treats pain, is also preparing to explore a sale, Reuters reported last week. In recent months, Allergan Plc (AGN.N), one of the biggest players in the central nervous system sector, has been seeking to deploy around $20... Read more
7d
CNBC
Allergan CEO says 'the American people deserve to be angry' at price gougingSaunders added that the performance of Allergan's stock stems from a change in
Allergan CEO says 'the American people deserve to be angry' at price gouging
CNBC / Posted 7 days ago
Saunders added that the performance of Allergan's stock stems from a change in shareholder base as a result of the Teva Pharmaceuticals deal and failed deal with Pfizer this year, bad publicity for the companies engaged in price gouging and the... Read more
8d
DW
UN plans response to rising antibiotic resistance |treatments. Ahead of this, 13 leading pharmaceutical companies worldwide - inc
UN plans response to rising antibiotic resistance |
DW / Posted 8 days ago
treatments. Ahead of this, 13 leading pharmaceutical companies worldwide - including Pfizer, Novartis, GlaxoSmithKline, Allergan, Cipla, Wockhardt and Germany's Merck - signed the declaration. The group planned to work with independent experts,... Read more
11 related stories
8d
Daily Herald
Machinery makers lead US stocks higher in early tradingalso struggled with discounts from competitors and shaky demand. Its stock lost
Machinery makers lead US stocks higher in early trading
Daily Herald / Posted 8 days ago
also struggled with discounts from competitors and shaky demand. Its stock lost $2.29, or 28.2 percent, to $5.83. ANOTHER ALLERGAN DEAL: Allergan, the maker of Botox, announced yet another acquisition as it agreed to buy liver disease drug... Read more
8d
Boston Globe
Stocks creep higher as Fed meeting startsand Dress Barn) fell 30 percent to a six-year low on weak quarterly results and
Stocks creep higher as Fed meeting starts
Boston Globe / Posted 8 days ago
and Dress Barn) fell 30 percent to a six-year low on weak quarterly results and a forecast that fell short of expectations. Allergan, the maker of Botox, announced yet another acquisition: Tobira Therapeutics, which is studying drugs to treat... Read more
3 related stories
8d
San Francisco Chronicle
SF biotech firm Tobira bought by AllerganAllergan’s agreement to buy San Francisco’s Tobira Therapeutics for as much as
SF biotech firm Tobira bought by Allergan
San Francisco Chronicle / Posted 8 days ago
Allergan’s agreement to buy San Francisco’s Tobira Therapeutics for as much as $1.7 billion sent biotech stocks soaring Tuesday, as investors bet that buyers will emerge for other companies developing experimental treatments for a severe liver... Read more
19 related stories
8d
Australian Broadcasting Corporation
Investors keep to sidelines ahead of US, BoJ decisionswhen it will. Gains in the healthcare sector offset weakness in energy stocks.
Investors keep to sidelines ahead of US, BoJ decisions
Australian Broadcasting Corporation / Posted 8 days ago
when it will. Gains in the healthcare sector offset weakness in energy stocks. Gilead Sciences jumped 3.5 per cent, while Allergan lost 2.7 per cent after announcing it will pay $US1.7 billion to buy Tobira Therapeutics. Among the energy... Read more
8d
TheBull
US stocks barely higher ahead of Fed announcementwhich specializes in remedies for liver disease, surged more than eight-fold on
US stocks barely higher ahead of Fed announcement
TheBull / Posted 8 days ago
which specializes in remedies for liver disease, surged more than eight-fold on news it agreed to be acquired by Allergan for $1.7 billion. Allergan lost 2.7 percent. Other biotech shares were boosted, with Amgen and Biogen winning more... Read more
2 related stories
8d
Fortune
Why Allergan Is Willing to Pay so Much Money for This BiotechAllergan agn wants to snap up liver disease drug maker Tobira Therapeutics tbra
Why Allergan Is Willing to Pay so Much Money for This Biotech
Fortune / Posted 8 days ago
Allergan agn wants to snap up liver disease drug maker Tobira Therapeutics tbra—and it’s willing to spend an unusually massive amount of cash to do it. The pharma giant announced Tuesday that it struck a deal to buy the California biotech for an... Read more
19 related stories
More

People in this news